Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTAC-0001 plus Pembrolizumab in mTNBC
NCT03720431Phase 1Unknown
- Sponsor
- PharmAbcine
- Start
- Jan 2019
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olinvacimab in triple-negative breast cancer (TNBC), sponsored by PharmAbcine. Primary endpoints: Dose limiting toxicities at 21 days, Adverse events up to 2 years and 1 more. Status: unknown.
02
Drugs
olinvacimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03720431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03720431.